These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 11078237)

  • 41. Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia.
    Isaacsohn JL; LaSalle J; Chao G; Gonasun L
    Clin Ther; 2003 Mar; 25(3):904-18. PubMed ID: 12852707
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients.
    Martínez-Castelao A; Grinyó JM; Fiol C; Castiñeiras MJ; Hurtado I; Gil-Vernet S; Serón D; Porta I; Miñarro A; Villarroya A; Alsina J
    Kidney Int Suppl; 1999 Jul; 71():S231-4. PubMed ID: 10412785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
    Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
    Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate].
    Widimský J; Hulínský V; Balazovjech I; Lánská V
    Vnitr Lek; 1999 Apr; 45(4):210-6. PubMed ID: 11045181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin.
    Lye M; Valacio R; Reckless JP; Ghosh AK; Findlay IN; Ghosh MK; Passmore AP; Fulcher RA
    Coron Artery Dis; 1998; 9(9):583-90. PubMed ID: 9861520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of fluvastatin and fenofibrate on the antioxidative barrier enzyme activity in patients with dyslipidemia].
    Kowalski J; Olejniczak J; Błaszczyk J; Błaszczyk-Suszyńska J; Kowalski M; Petecka E; Kedziora J
    Pol Merkur Lekarski; 2003 Apr; 14(82):285-8. PubMed ID: 12868185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia.
    Knopp RH; Frohlich J; Jokubaitis LA; Dawson K; Broyles FE; Gomez-Coronado D
    Am J Med; 1994 Jun; 96(6A):69S-78S. PubMed ID: 8017470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database.
    Peters TK; Mehra M; Muratti EN
    Am J Hypertens; 1993 Nov; 6(11 Pt 2):340S-345S. PubMed ID: 8297542
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia.
    Haak E; Abletshauser C; Weber S; Goedicke C; Martin N; Hermanns N; Lackner K; Kusterer K; Usadel KH; Haak T
    Atherosclerosis; 2001 Apr; 155(2):395-401. PubMed ID: 11254910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of treatment with low-dose fluvastatin in hypercholesterolemic renal transplant recipients.
    Akiyama T; Ishii T; Imanishi M; Nishioka T; Matsuura T; Kurita T
    Transplant Proc; 2001 May; 33(3):2115-8. PubMed ID: 11377469
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
    Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
    JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety.
    Davidson MH
    Am J Med; 1994 Jun; 96(6A):41S-44S. PubMed ID: 8017466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
    Davidson MH; Palmisano J; Wilson H; Liss C; Dicklin MR
    Clin Ther; 2003 Nov; 25(11):2738-53. PubMed ID: 14693301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
    Leitersdorf E; Muratti EN; Eliav O; Meiner V; Eisenberg S; Dann EJ; Sehayek E; Peters TK; Stein Y
    Am J Med; 1994 May; 96(5):401-7. PubMed ID: 8192170
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S; Gamez R; Mas R; Goicochea E
    Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition.
    Bard JM; Dallongeville J; Hagen E; Pfister P; Ose L; Fruchart JC; Duriez P
    Metabolism; 1995 Nov; 44(11):1447-54. PubMed ID: 7476333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of fluvastatin on human biliary lipids.
    Tazuma S; Ohya T; Mizuno T; Takizawa I; Kunita T; Takata K; Hayashi K; Hino F; Tokumo H; Watanabe T
    Am J Cardiol; 1995 Jul; 76(2):110A-113A. PubMed ID: 7604783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effect of fluvastatin and fenofibrate on reactive oxygen species generation and lipid peroxidation in patients with dyslipidemia].
    Kowalski J; Błaszczyk J; Olejniczak J; Kowalski M; Błaszczyk-Suszyńska J; Petecka E; Kedziora J; Gburek J
    Pol Merkur Lekarski; 2003 Apr; 14(82):279-84. PubMed ID: 12868184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.